Healthcare: Should You Stick With Gilead Sciences?
Industry Focus - Ein Podcast von The Motley Fool
Kategorien:
Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD
